Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma
- 1 April 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (7) , 1985-1992
- https://doi.org/10.1200/jco.2001.19.7.1985
Abstract
PURPOSE: Flavopiridol is the first cyclin-dependent kinase inhibitor to enter clinical trials. Activity in gastric cancer xenografts and in a patient with gastric cancer on the phase I trial led to...Keywords
This publication has 9 references indexed in Scilit:
- Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium StudyJournal of Clinical Oncology, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.Journal of Clinical Oncology, 1998
- Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methodsJournal of Immunological Methods, 1997
- The Novel Cyclin-Dependent Kinase Inhibitor Flavopiridol Downregulates Bcl-2 and Induces Growth Arrest and Apoptosis in Chronic B-Cell Leukemia LinesBlood, 1997
- Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275Biochemical and Biophysical Research Communications, 1994
- Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells: Correlation with decreased H1 kinase activityBiochemical Pharmacology, 1993
- Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275JNCI Journal of the National Cancer Institute, 1992
- An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum : isolation, structure and total synthesisTetrahedron, 1988